Relmada Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2016
Filed with the SEC on May 9, 2016 and accepted by EDGAR at May 9, 2016, 17:13 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2016-01-01 to 2016-03-31 | $609.1k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2015-07-01 to 2016-03-31 | $5.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2016-01-01 to 2016-03-31 | −$2.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2015-07-01 to 2016-03-31 | −$13.1m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2016-01-01 to 2016-03-31 | −$1.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months2015-07-01 to 2016-03-31 | $342.7k | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-01-01 to 2016-03-31 | −$0.15 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2015-07-01 to 2016-03-31 | $0.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-01-01 to 2016-03-31 | −$0.15 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2015-07-01 to 2016-03-31 | $0.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-01-01 to 2016-03-31 | 12,003,789 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2015-07-01 to 2016-03-31 | 12,137,518 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2015-07-01 to 2016-03-31 | −$10.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2015-07-01 to 2016-03-31 | $539.2k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | At period end2016-03-31 | $11.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-03-31 | $11.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2016-03-31 | $12.7m | us-gaap:Assets |
| Current liabilities | At period end2016-03-31 | $2.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-03-31 | $2.5m | us-gaap:Liabilities |
| Shareholders' equity | At period end2016-03-31 | $10.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-16-013088. Last ingested by Listed: Nov 13, 2026, 15:42 ET. Listed shows no prices and gives no investment advice.